TLSI (TriSalus Life Sciences) Accounts Payable : $1.45 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Accounts Payable?

TriSalus Life Sciences's Accounts Payable for the quarter that ended in Sep. 2024 was $1.45 Mil.

TriSalus Life Sciences's quarterly Accounts Payable declined from Mar. 2024 ($2.35 Mil) to Jun. 2024 ($1.98 Mil) and declined from Jun. 2024 ($1.98 Mil) to Sep. 2024 ($1.45 Mil).

TriSalus Life Sciences's annual Accounts Payable increased from Dec. 2021 ($1.30 Mil) to Dec. 2022 ($4.95 Mil) but then declined from Dec. 2022 ($4.95 Mil) to Dec. 2023 ($3.39 Mil).

TriSalus Life Sciences Accounts Payable Historical Data

The historical data trend for TriSalus Life Sciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences Accounts Payable Chart

TriSalus Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable

1.30

4.95

3.39

TriSalus Life Sciences Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable	Get a 7-Day Free Trial						1.90	3.39	2.35	1.98	1.45

TriSalus Life Sciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

TriSalus Life Sciences Accounts Payable Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

6272 W. 91st Avenue, Westminster, CO, USA, 80031

Website

https://www.trisaluslifesci.com

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines?Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Executives

Mats Wahlstrom	director, 10 percent owner	500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Mary T Szela	director, officer: CEO and President	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
George Kelly Martin	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jodi Devlin	officer: President, Therapeutics	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih	officer: President, Device Technology	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox	officer: Chief Scientific & Manufact.	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks	director	C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
Jennifer Stevens	officer: Chief Regulatory Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak	officer: Sr.VP, Corp. Dev. & Strategy	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Anil K. Singhal	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy	director, officer: Chief Financial Officer	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz	officer: Chief Medical Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius	10 percent owner	BOX 984, BORAS V7 SE-501 10